| B cells and tertiary lymphoid structures promote immunotherapy response BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, ... Nature 577 (7791), 549-555, 2020 | 2555 | 2020 |
| Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma CU Blank, EA Rozeman, LF Fanchi, K Sikorska, B van de Wiel, ... Nature medicine 24 (11), 1655-1661, 2018 | 939 | 2018 |
| Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma J Müller, O Krijgsman, J Tsoi, L Robert, W Hugo, C Song, X Kong, ... Nature communications 5 (1), 5712, 2014 | 813 | 2014 |
| Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2 … EA Rozeman, AM Menzies, ACJ van Akkooi, C Adhikari, C Bierman, ... The lancet oncology 20 (7), 948-960, 2019 | 571 | 2019 |
| Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases F Weeber, M Van De Wetering, M Hoogstraat, KK Dijkstra, O Krijgsman, ... Proceedings of the National Academy of Sciences 112 (43), 13308-13311, 2015 | 527 | 2015 |
| Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma EA Rozeman, EP Hoefsmit, ILM Reijers, RPM Saw, JM Versluis, ... Nature medicine 27 (2), 256-263, 2021 | 346 | 2021 |
| Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy K Renner, C Bruss, A Schnell, G Koehl, HM Becker, M Fante, ... Cell reports 29 (1), 135-150. e9, 2019 | 329 | 2019 |
| Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma JL Vos, JBW Elbers, O Krijgsman, JJH Traets, X Qiao, AM van der Leun, ... Nature communications 12 (1), 7348, 2021 | 323 | 2021 |
| Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold DW Vredevoogd, T Kuilman, MA Ligtenberg, J Boshuizen, KE Stecker, ... Cell 178 (3), 585-599. e15, 2019 | 261 | 2019 |
| CopywriteR: DNA copy number detection from off-target sequence data T Kuilman, A Velds, K Kemper, M Ranzani, L Bombardelli, M Hoogstraat, ... Genome biology 16 (1), 49, 2015 | 252 | 2015 |
| Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors J Boshuizen, LA Koopman, O Krijgsman, A Shahrabi, EG van den Heuvel, ... Nature medicine 24 (2), 203-212, 2018 | 233 | 2018 |
| A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response O Krijgsman, P Roepman, W Zwart, JS Carroll, S Tian, FA de Snoo, ... Breast cancer research and treatment 133 (1), 37-47, 2012 | 199 | 2012 |
| Intra‐and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts K Kemper, O Krijgsman, P Cornelissen‐Steijger, A Shahrabi, F Weeber, ... EMBO molecular medicine 7 (9), 1104-1118, 2015 | 169 | 2015 |
| Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastatic disease in patients EA Semenova, M Kwon, K Monkhorst, JY Song, R Bhaskaran, ... Cell reports 16 (3), 631-643, 2016 | 168 | 2016 |
| Focal aberrations indicate EYA2 and hsa‐miR‐375 as oncogene and tumor suppressor in cervical carcinogenesis M Bierkens, O Krijgsman, SM Wilting, L Bosch, A Jaspers, GA Meijer, ... Genes, Chromosomes and Cancer 52 (1), 56-68, 2013 | 167 | 2013 |
| TSPYL5 suppresses p53 levels and function by physical interaction with USP7 MT Epping, LAT Meijer, O Krijgsman, JL Bos, PP Pandolfi, R Bernards Nature cell biology 13 (1), 102-108, 2011 | 160 | 2011 |
| Integrative epigenetic taxonomy of primary prostate cancer S Stelloo, E Nevedomskaya, Y Kim, K Schuurman, E Valle-Encinas, ... Nature communications 9 (1), 4900, 2018 | 159 | 2018 |
| XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data RJC Kluin, K Kemper, T Kuilman, JR de Ruiter, V Iyer, JV Forment, ... BMC bioinformatics 19 (1), 366, 2018 | 151 | 2018 |
| PRAME expression and clinical outcome of breast cancer MT Epping, AAM Hart, AM Glas, O Krijgsman, R Bernards British journal of cancer 99 (3), 398-403, 2008 | 149 | 2008 |
| Reversal of pre-existing NGFR-driven tumor and immune therapy resistance J Boshuizen, DW Vredevoogd, O Krijgsman, MA Ligtenberg, ... Nature communications 11 (1), 3946, 2020 | 124 | 2020 |
Blank cNetherlands Cancer InstituteVerified email at nki.nl
